Stock 2157 LEPU BIOPHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lepu Biopharma Co., Ltd.

Equities

2157

CNE100004SM4

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:27 2024-07-12 am EDT 		5-day change 1st Jan Change
3.47 HKD +5.79% Intraday chart for Lepu Biopharma Co., Ltd. -3.34% -17.58%
May. 24 Lepu Biopharma to Present Three Studies During US Cancer Meet; Shares Dip 7% MT
May. 24 Lepu Biopharma Co., Ltd. Announces Three Clinical Trial Results Presented At 2024 Asco Annual Meeting CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 10,772 6,350 5,512 - -
Enterprise Value (EV) 1 10,786 6,666 6,137 6,332 5,055
P/E ratio - - - - -
Yield - - - - -
Capitalization / Revenue 692 x 28.2 x 19.7 x 20.4 x 5.57 x
EV / Revenue 693 x 29.6 x 21.9 x 23.4 x 5.11 x
EV / EBITDA -19.4 x -23.1 x -29.5 x -20.4 x -44.3 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book 12 x 7.08 x 8.48 x 16.1 x 32.2 x
Nbr of stocks (in thousands) 1,659,445 1,659,445 1,710,615 - -
Reference price 2 6.491 3.827 3.222 3.222 3.222
Announcement Date 3/17/23 3/27/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 15.57 225.4 279.8 270.3 989
EBITDA 1 -555.9 -288.4 -208.3 -310.6 -114.2
EBIT 1 -704.5 -391 -371.3 -470.8 -267.7
Operating Margin -4,524.03% -173.48% -132.74% -174.19% -27.07%
Earnings before Tax (EBT) - - - - -
Net income - - - - -
Net margin - - - - -
EPS - - - - -
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share 2 - - - - -
Announcement Date 3/17/23 3/27/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt 1 14.2 316 626 820 -
Net Cash position 1 - - - - 457
Leverage (Debt/EBITDA) -0.0255 x -1.095 x -3.003 x -2.64 x -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) -79.3% -2.46% -34% -61.8% -65.1%
ROA (Net income/ Total Assets) - - - - -
Assets - - - - -
Book Value Per Share 2 0.5400 0.5400 0.3800 0.2000 0.1000
Cash Flow per Share - - - - -
Capex - - - - -
Capex / Sales - - - - -
Announcement Date 3/17/23 3/27/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Lepu Biopharma Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.222 CNY
Average target price
4.613 CNY
Spread / Average Target
+43.17%
Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LEPU BIOPHARMA CO., LTD. Stock Lepu Biopharma Co., Ltd.
-17.58% 719M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.12% 127B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+25.25% 117B
ARGENX SE Stock argenx SE
+25.56% 27.77B
BIONTECH SE Stock BioNTech SE
-19.51% 20.44B
GENMAB A/S Stock Genmab A/S
-14.36% 16.62B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.63% 15.92B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.67% 14.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.89% 14.74B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.74% 14.38B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2157 Stock
  4. Financials Lepu Biopharma Co., Ltd.